Clinical Trial News Archive - March 2022
March 1, 2022
- Phase 3 CLOVER Trial for Pfizer’s Investigational Clostridioides Difficile Vaccine Indicates Strong Potential Effect in Reducing Duration and Severity of Disease Based on Secondary Endpoints
- Jardiance provided a significant clinical benefit in adults stabilized in hospital following acute heart failure in EMPULSE phase III trial
March 2, 2022
- Jefferson Health Makes Strides in Treating Loss of Smell and Taste
- Pfizer Granted FDA Breakthrough Therapy Designation for Respiratory Syncytial Virus (RSV) Vaccine Candidate for the Prevention of RSV in Infants from Birth up to Six Months of Age by Active Immunization of Pregnant Women
March 3, 2022
- Nirsevimab Significantly Protected Infants Against RSV Disease in Phase 3 Trial
- Fulcrum Therapeutics Announces REACH, a Phase 3 Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy
- BioLineRx Announces Additional Positive Results from Pharmacoeconomic Study Comparing Motixafortide + G-CSF to Plerixafor + G-CSF in Stem Cell Mobilization
March 4, 2022
- Aravax announces opening of IND for Phase 2 clinical trials of PVX108, a next-generation immunotherapy for the treatment of peanut allergy
- Coherus and Junshi Biosciences Announce Positive Results from Phase 3 Esophageal Cancer Study of Toripalimab Published in Cancer Cell
March 7, 2022
- Phase 3 TROPiCS-02 Study Met the Primary Endpoint of Progression-Free Survival in Late-Line HR+/HER2- Metastatic Breast Cancer
- Astellas Announces Topline Results from Long-Term Phase 3 Safety Study of Fezolinetant which Inform Future Regulatory Filings for the Treatment of Vasomotor Symptoms Associated with Menopause
- Curis Announces Gastroenterology Publication of Encouraging Preclinical Data of Emavusertib in Pancreatic Cancers
March 8, 2022
March 9, 2022
- Metastatic Tumor Treatment with Novel GPX Embolic Device
- Efanesoctocog Alfa Met Primary And Key Secondary Endpoints in Pivotal Study in Hemophilia A, Demonstrating Superiority To Prior Factor Prophylaxis Treatment
- Pfizer Initiates Phase 2/3 Study of Novel COVID-19 Oral Treatment in Pediatric Participants
- NIH Launches Trial to Study Allergic Reactions to COVID-19 mRNA Vaccine
March 10, 2022
- AbbVie Announces Positive Phase 3 Atogepant (QULIPTA) Data for the Preventive Treatment of Chronic Migraine
- Moderna Announces First Participant Dosed in Phase 2 Study of Omicron-Specific Bivalent Booster Candidate
- Venatorx Pharmaceuticals Announces Positive Results for Phase 3 Clinical Trial (CERTAIN-1) of Cefepime-Taniborbactam for Treatment of cUTI
March 11, 2022
March 14, 2022
- Corium Receives FDA Approval of ADLARITY (donepezil transdermal system) for Treatment of Patients with Alzheimer's Disease
- Bristol Myers Squibb and Nektar Announce Update on Phase 3 PIVOT IO-001 Trial Evaluating Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab) in Previously Untreated Unresectable or Metastatic Melanoma
- NIH Launches Clinical Trial of Three mRNA HIV Vaccines
March 15, 2022
- Anavasi Diagnostics Announces FDA EUA Submission for Its COVID-19 Test
- Moderna Announces First Participant Dosed in Phase 1 Study of its HIV Trimer mRNA Vaccine
- Pfizer and BioNTech Submit for U.S. Emergency Use Authorization of an Additional Booster Dose of their COVID-19 Vaccine for Older Adults
March 16, 2022
- Amicus Therapeutics Announces Positive Long-Term Data from Phase 1/2 Study of AT-GAA in Pompe Disease at the 2022 MDA Clinical & Scientific Conference
- Jardiance phase III EMPA-KIDNEY trial will stop early due to clear positive efficacy in people with chronic kidney disease
- Lynparza (olaparib) Reduced Risk of Death by 32% in Patients With Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer in Phase 3 OlympiA Trial
March 17, 2022
- Moderna Submits Amendment to the Emergency Use Authorization for an Additional Booster Dose of its COVID-19 Vaccine in the U.S.
- SciSparc Announces Positive Results from Psychedelic-Based Pre-Clinical Trial
- Tetra Bio-Pharma's Qixleef on Track After Type C Meeting with U.S. FDA
March 18, 2022
- Paradigm Biopharmaceuticals Initiates a Phase 3 Clinical Trial in Knee Osteoarthritis Across the U.S.
- Amylyx Pharmaceuticals Announces Launch of U.S. Expanded Access Program for AMX0035
March 21, 2022
- Pulmatrix Announces Positive Top-Line Data Evaluating PUR1800 in Patients with Stable COPD
- Vallon Pharmaceuticals Announces Topline Results of its Pivotal SEAL Study for Lead Program, ADAIR, for the Treatment of ADHD
March 22, 2022
March 23, 2022
- Moderna Announces its COVID-19 Vaccine Phase 2/3 Study in Children 6 Months to Under 6 Years Has Successfully Met Its Primary Endpoint
- Pfizer Announces Positive Top-Line Results for Phase 3 Trial of Etrasimod in Ulcerative Colitis Patients
March 24, 2022
- Pfizer Granted FDA Breakthrough Therapy Designation for Respiratory Syncytial Virus Vaccine Candidate for the Prevention of RSV in Older Adults
- New clinical trial collaboration for Cu-64 SAR-bisPSMA in prostate cancer
March 25, 2022
- US Food and Drug Administration Revises Emergency Use Authorization for Sotrovimab due to Omicron BA.2 Subvariant
- Novavax Announces Participation in Two Booster Studies Using its COVID-19 Vaccine
- Dermavant Showcases New Long-Term Durability and Tolerability Data from Phase 3 PSOARING 3 Trial of Tapinarof Cream for Adults with Plaque Psoriasis at the 2022 AAD Annual Meeting
March 26, 2022
March 28, 2022
- New Spesolimab Data Showed Significant Improvement in Patients with Generalized Pustular Psoriasis (GPP) Flares
- Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis
March 29, 2022
- Genentech Provides Update on Tiragolumab Phase III SKYSCRAPER-02 Study in Extensive-Stage Small Cell Lung Cancer
- Moderna Receives FDA Approval for Emergency Use Authorization of 2nd Booster Dose of Its COVID-19 Vaccine, mRNA-1273
- Pfizer Announces Positive Top-line Results from Yearlong Phase 3 Trial of Etrasimod in Ulcerative Colitis, Underscoring Best-in-Class Potential
- Diamond Therapeutics Achieves Last Patient Last Visit in Clinical Trial of Low-Dose Psilocybin
- Ocuphire Announces Positive Topline Results from MIRA-3 Phase 3 FDA Registration Trial for Nyxol® in the Reversal of Mydriasis
- Pfizer and BioNTech Receive Expanded U.S. Emergency Use Authorization for an Additional COVID-19 Vaccine Booster in Individuals Aged 50 Years and Older
March 30, 2022
March 31, 2022
- Vertex Announces Statistically Significant and Clinically Meaningful Results From Two Phase 2 Proof-of-Concept Studies of VX-548 for the Treatment of Acute Pain
- Cerevance Reports Positive Phase 2 Clinical Trial Results with CVN424, a Parkinson’s Disease Drug Working Through a New Mechanism
- Sorrento Reports FDA Clearance for the Commencement of a Phase 2/3 Study for Abivertinib in Treatment of Hospitalized Patients With Severe Pneumonia Due to COVID-19
Clinical trial results archive
- 2024
- January, February, March, April, May
- 2023
- January, February, March, April, May, June, July, August, September, October, November, December
- 2022
- January, February, March, April, May, June, July, August, September, October, November, December
- 2021
- January, February, March, April, May, June, July, August, September, October, November, December
- 2020
- January, February, March, April, May, June, July, August, September, October, November, December
- 2019
- January, February, March, April, May, June, July, August, September, October, November, December
- 2018
- January, February, March, April, May, June, July, August, September, October, November, December
- 2017
- May, June, July, August, September, October, November, December
- 2016
- October
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.